Amylyx Pharmaceuticals, Inc. Co-Chief Executive Officer Joshua B. Cohen filed a Form 4 on November 12, 2026, reporting the sale of 100,000 shares of common stock on November 9, 2026, pursuant to a Rule 10b5-1 trading plan.
Key Highlights
- Reporting person: Joshua B. Cohen, Director and Co-Chief Executive Officer of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)
- First sale tranche: 38,105 shares disposed of on November 9, 2026, at a weighted average price of $29.3933, with individual transaction prices ranging from $28.74 to $29.73
- Second sale tranche: 61,895 shares disposed of on November 9, 2026, at a weighted average price of $30.1098, with individual transaction prices ranging from $29.74 to $30.29
- Total shares sold: 100,000 shares of common stock disposed of across both tranches
- Post-transaction ownership: 3,513,123 shares of common stock held directly following the reported transactions
- 10b5-1 plan: Both sales were effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026
Cohen's Two-Tranche Sale of Amylyx Common Stock
According to the filing, Joshua B. Cohen, who serves as both a Director and Co-Chief Executive Officer of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), disposed of a total of 100,000 shares of common stock on November 9, 2026. The transactions were reported in a Form 4 filed with the SEC on November 12, 2026, and were designated with transaction code "S," indicating open-market sales.
The filing reports two separate tranches of sales. The first involved 38,105 shares sold at a weighted average price of $29.3933, with individual prices ranging from $28.74 to $29.73 per share. The second involved 61,895 shares sold at a weighted average price of $30.1098, with individual prices ranging from $29.74 to $30.29 per share. The filing notes that full information regarding the number of shares sold at each separate price within each tranche can be furnished to the SEC staff upon request.
Both tranches were executed pursuant to a Rule 10b5-1 trading plan that Cohen adopted on May 11, 2026, according to the filing. Following the reported transactions, Cohen directly held 3,513,123 shares of Amylyx Pharmaceuticals common stock, the filing stated. No derivative securities transactions were reported in this filing.
What Was Disclosed
The Form 4 disclosed two open-market sales of Amylyx Pharmaceuticals common stock by Co-CEO Joshua B. Cohen on November 9, 2026, totaling 100,000 shares across two tranches, carried out under a pre-established Rule 10b5-1 trading plan adopted May 11, 2026.



Please wait processing your request...